Celsion Corporation (NASDAQ:CLSN) has received an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $14.50.

CLSN has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Tuesday, August 29th. ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Maxim Group raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Wednesday, October 4th. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of Celsion Corporation in a research note on Tuesday. They issued an “outperform” rating and a $9.00 price objective on the stock.

Shares of Celsion Corporation (CLSN) traded up $0.14 during mid-day trading on Tuesday, reaching $2.14. 3,071,400 shares of the company’s stock traded hands, compared to its average volume of 1,429,227. Celsion Corporation has a 1 year low of $1.24 and a 1 year high of $12.46.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/celsion-corporation-clsn-given-average-recommendation-of-buy-by-analysts/1718261.html.

A hedge fund recently raised its stake in Celsion Corporation stock. Renaissance Technologies LLC grew its stake in shares of Celsion Corporation (NASDAQ:CLSN) by 100.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,375,147 shares of the biotechnology company’s stock after purchasing an additional 690,349 shares during the period. Renaissance Technologies LLC owned approximately 2.48% of Celsion Corporation worth $397,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.41% of the company’s stock.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.